An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers

Human Molecular Genetics

Volumn 21, Issue 7, 2012, Pages 1470-1480

  Wen, Yujia ^a   Gamazon, Eric R ^a   Bleibel, Wasim K ^a   Wing, Claudia ^a   Mi, Shuangli ^a   Mcilwee, Bridget E ^a   Delaney, Shannon M ^a   Duan, Shiwei ^a   Im, Hae Kyung ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEMETREXED; PROTEIN CTTN; PROTEIN ZMAT3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; CORTACTIN; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; GLUTAMATES; GUANINE; HUMANS; LINEAR MODELS; LYMPHOCYTES; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT LOCI;

EID: 84858221025     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr583     Document Type: Article

References (53)

1. Rossi, A., Ricciardi, S., Maione, P., de Marinis, F. and Gridelli, C. (2009) Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer, 66, 141-149.
2. Ceresoli, G.L., Zucali, P.A., Gianoncelli, L., Lorenzi, E. and Santoro, A. (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat. Rev., 36, 24-32.
3. Chattopadhyay, S., Moran, R.G. and Goldman, I.D. (2007) Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol. Cancer Ther., 6, 404-417.
4. Fossella, F.V. and Gatzemeier, U. (2002) Phase I trials of pemetrexed. Semin. Oncol., 29, 8-16.
5. Longo-Sorbello, G.S., Chen, B., Budak-Alpdogan, T. and Bertino, J.R. (2007) Role of pemetrexed in non-small cell lung cancer. Cancer Invest., 25, 59-66.
6. Pio-Asin, M., Segrelles-Bellmunt, G., Arrondo-Velasco, A. and Sarobe-Carricas, M. (2009) Acute myocardial infarction and pemetrexed. Farm Hosp., 33, 114-115.
7. Brandes, J.C., Grossman, S.A. and Ahmad, H. (2006) Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest., 24, 283-287.
8. Vootukuru, V., Liew, Y.P. and Nally, J.V. Jr. (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med. Oncol., 23, 419-422.
9. Hanauske, A.R., Eismann, U., Oberschmidt, O., Pospisil, H., Hoffmann, S., Hanauske-Abel, H., Ma, D., Chen, V., Paoletti, P. and Niyikiza, C. (2007) In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest. New Drugs, 25, 417-423.
10. Niyikiza, C., Baker, S.D., Seitz, D.E., Walling, J.M., Nelson, K., Rusthoven, J.J., Stabler, S.P., Paoletti, P., Calvert, A.H. and Allen, R.H. (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther., 1, 545-552.
11. Li, K.M., Rivory, L.P. and Clarke, S.J. (2007) Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Br. J. Cancer, 97, 1071-1076.
12. Welsh, M., Mangravite, L., Medina, M.W., Tantisira, K., Zhang, W., Huang, R.S., McLeod, H. and Dolan, M.E. (2009) Pharmacogenomic discovery using cell-based models. Pharmacol. Rev., 61, 413-429.
13. Huang, R.S., Duan, S., Shukla, S.J., Kistner, E.O., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E. and Dolan, M.E. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet., 81, 427-437.
14. Huang, R.S., Duan, S., Bleibel, W.K., Kistner, E.O., Zhang, W., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox, N.J. et al. (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl Acad. Sci. USA, 104, 9758-9763.
15. Hartford, C.M., Duan, S., Delaney, S.M., Mi, S., Kistner, E.O., Lamba, J.K., Huang, R.S. and Dolan, M.E. (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood, 113, 2145-2153.
16. Gamazon, E.R., Nicolae, D.L. and Cox, N.J. (2011) A study of CNVs as trait-associated polymorphisms and as expression quantitative trait loci. PLoS Genet., 7, e1001292.
17. Huang, R.S., Johnatty, S.E., Gamazon, E., Im, H.K., Ziliak, D., Duan, S., Zhang, W., Kistner, E.O., Chen, P., Beesley, J. et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res., 17, 5490-5500.
18. Ziliak, D., O'Donnell, P.H., Im, H.K., Gamazon, E.R., Chen, P., Delaney, S., Shukla, S., Das, S., Cox, N.J., Vokes, E.E. et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl. Res., 157, 265-272.
19. Ingle, J.N., Schaid, D.J., Goss, P.E., Liu, M., Mushiroda, T., Chapman, J.A., Kubo, M., Jenkins, G.D., Batzler, A., Shepherd, L. et al. (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol., 28, 4674-4682.
20. Chen, S.H., Yang, W., Fan, Y., Stocco, G., Crews, K.R., Yang, J.J., Paugh, S.W., Pui, C.H., Evans, W.E. and Relling, M.V. (2010) A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 25, 66-74.
21. Abecasis, G.R., Cardon, L.R. and Cookson, W.O. (2000) A general test of association for quantitative traits in nuclear families. Am. J. Hum. Genet., 66, 279-292.
22. Devlin, B. and Roeder, K. (1999) Genomic control for association studies. Biometrics, 55, 997-1004.
23. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
24. Zhang, W., Duan, S., Kistner, E.O., Bleibel, W.K., Huang, R.S., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox, N.J. et al. (2008) Evaluation of genetic variation contributing to differences in gene expression between populations. Am. J. Hum. Genet., 82, 631-640.
25. Gamazon, E.R., Zhang, W., Konkashbaev, A., Duan, S., Kistner, E.O., Nicolae, D.L., Dolan, M.E. and Cox, N.J. (2010) SCAN: SNP and copy number annotation. Bioinformatics, 26, 259-262.
26. Gamazon, E.R., Huang, R.S., Cox, N.J. and Dolan, M.E. (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl Acad. Sci. USA, 107, 9287-9292.
27. Wang, P., Dai, M., Xuan, W., McEachin, R.C., Jackson, A.U., Scott, L.J., Athey, B., Watson, S.J. and Meng, F. (2006) SNP Function Portal: a web database for exploring the function implication of SNP alleles. Bioinformatics, 22, e523-e529.
28. Huang, R.S., Kistner, E.O., Bleibel, W.K., Shukla, S.J. and Dolan, M.E. (2007) Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol. Cancer Ther., 6, 31-36.
29. Caliskan, M., Cusanovich, D.A., Ober, C. and Gilad, Y. (2011) The effects of EBV transformation on gene expression levels and methylation profiles. Hum. Mol. Genet., 20, 1643-1652.
30. Nicolae, D.L., Gamazon, E., Zhang, W., Duan, S., Dolan, M.E. and Cox, N.J. (2010) Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet., 6, e1000888.
31. Buday, L. and Downward, J. (2007) Roles of cortactin in tumor pathogenesis. Biochim. Biophys. Acta, 1775, 263-273.
32. Weaver, A.M. (2008) Cortactin in tumor invasiveness. Cancer Lett., 265, 157-166.
33. Ormandy, C.J., Musgrove, E.A., Hui, R., Daly, R.J. and Sutherland, R.L. (2003) Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat., 78, 323-335.
34. Schuuring, E. (1995) The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene, 159, 83-96.
35. Hofman, P., Butori, C., Havet, K., Hofman, V., Selva, E., Guevara, N., Santini, J. and Van Obberghen-Schilling, E. (2008) Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status. Br. J. Cancer, 98, 956-964.
36. Gibcus, J.H., Mastik, M.F., Menkema, L., de Bock, G.H., Kluin, P.M., Schuuring, E. and van der Wal, J.E. (2008) Cortactin expression predicts poor survival in laryngeal carcinoma. Br. J. Cancer, 98, 950-955.
37. Ambrosio, E.P., Rosa, F.E., Domingues, M.A., Villacis, R.A., Coudry, R.D., Tagliarini, J.V., Soares, F.A., Kowalski, L.P. and Rogatto, S.R. (2011) Cortactin is associated with perineural invasion in the deep invasive front area of laryngeal carcinomas. Hum. Pathol., 42, 1221-1229.
38. Hui, A., Kulkarni, G.V., Hunter, W.L., McCulloch, C.A. and Cruz, T.F. (1997) Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Arthritis Rheum., 40, 1073-1084.
39. Wang, X., Cao, W., Mo, M., Wang, W., Wu, H. and Wang, J. (2010) VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J. Surg. Oncol., 102, 325-330.
40. Cai, J.H., Zhao, R., Zhu, J.W., Jin, X.L., Wan, F.J., Liu, K., Ji, X.P., Zhu, Y.B. and Zhu, Z.G. (2010) Expression of cortactin correlates with a poor prognosis in patients with stages II-III colorectal adenocarcinoma. J. Gastrointest. Surg., 14, 1248-1257.
41. Timpson, P., Wilson, A.S., Lehrbach, G.M., Sutherland, R.L., Musgrove, E.A. and Daly, R.J. (2007) Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res., 67, 9304-9314.
42. Timpson, P., Lynch, D.K., Schramek, D., Walker, F. and Daly, R.J. (2005) Cortactin overexpression inhibits ligand-induced down-regulation of the epidermal growth factor receptor. Cancer Res., 65, 3273-3280.
43. Lynch, D.K., Winata, S.C., Lyons, R.J., Hughes, W.E., Lehrbach, G.M., Wasinger, V., Corthals, G., Cordwell, S. and Daly, R.J. (2003) A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J. Biol. Chem., 278, 21805-21813.
44. Dedes, K.J., Lopez-Garcia, M.A., Geyer, F.C., Lambros, M.B., Savage, K., Vatcheva, R., Wilkerson, P., Wetterskog, D., Lacroix-Triki, M., Natrajan, R. et al. (2010) Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Res. Treat., 124, 653-666.
45. Hirooka, S., Akashi, T., Ando, N., Suzuki, Y., Ishida, N., Kurata, M., Takizawa, T., Kayamori, K., Sakamoto, K., Fujiwara, N. et al. (2011) Localization of the invadopodia-related proteins actinin-1 and cortactin to matrix-contact-side cytoplasm of cancer cells in surgically resected lung adenocarcinomas. Pathobiology, 78, 10-23.
46. Zhang, L., Liu, T., Huang, Y. and Liu, J. (2011) microRNA-182 inhibits the proliferation and invasion of human lung adenocarcinoma cells through its effect on human cortical actin-associated protein. Int. J. Mol. Med., 28, 381-388.
47. Vilborg, A., Bersani, C., Wilhelm, M.T. and Wiman, K.G. (2011) The p53 target Wig-1: a regulator of mRNA stability and stem cell fate? Cell Death Differ., 18, 1434-1440.
48. Vilborg, A., Glahder, J.A., Wilhelm, M.T., Bersani, C., Corcoran, M., Mahmoudi, S., Rosenstierne, M., Grander, D., Farnebo, M., Norrild, B. et al. (2009) The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc. Natl Acad. Sci. USA, 106, 15756-15761.
49. Prahl, M., Vilborg, A., Palmberg, C., Jornvall, H., Asker, C. and Wiman, K.G. (2008) The p53 target protein Wig-1 binds hnRNP A2/B1 and RNA Helicase A via RNA. FEBS Lett., 582, 2173-2177.
50. Hellborg, F., Qian, W., Mendez-Vidal, C., Asker, C., Kost-Alimova, M., Wilhelm, M., Imreh, S. and Wiman, K.G. (2001) Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene, 20, 5466-5474.
51. Mendez Vidal, C., Prahl, M. and Wiman, K.G. (2006) The p53-induced Wig-1 protein binds double-stranded RNAs with structural characteristics of siRNAs and miRNAs. FEBS Lett., 580, 4401-4408.
52. Gamazon, E.R., Duan, S., Zhang, W., Huang, R.S., Kistner, E.O., Dolan, M.E. and Cox, N.J. (2010) PACdb: a database for cell-based pharmacogenomics. Pharmacogenet. Genomics, 20, 269-273.
53. Huang, R.S., Duan, S., Kistner, E.O., Bleibel, W.K., Delaney, S.M., Fackenthal, D.L., Das, S. and Dolan, M.E. (2008) Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res., 68, 3161-3168.